New frontiers in the treatment of multiple myeloma.
New frontiers in the treatment of multiple myeloma.
复制标题
DOI：
10.1100/tsw.2006.236
复制
发表时间：
2006-12-06
影响因子：
--
通讯作者：
Anderson KC
中科院分区：
文献类型：
--
作者：
Hwang JJ;Ghobrial IM;Anderson KC
最近在阐明骨髓瘤生物学方面的飞跃，特别是细胞内途径和与骨髓微环境的复杂相互作用，导致了新型靶向治疗和治疗方案的前所未有的激增。目前有超过30种新药正在测试中的治疗多发性骨髓瘤（MM）。其中许多都是新型靶向药物，已证明具有显着的疗效和延长的生存期。在这篇综述中，我们总结了目前的理解的作用机制的新疗法正在测试中的临床前和临床设置在MM。这些药物直接作用于细胞内信号通路，细胞维护过程，和细胞表面受体。最后，我们提出了这些药物的临床反应时，单独使用或合并使用的MM患者的临床试验。事实上，MM已成为一个模型疾病的发展，新的治疗药物。
Recent leaps in elucidating the biology of myeloma, particularly the intracellular pathways and the complex interaction with the bone marrow microenvironment, have resulted in an unprecedented surge of novel, targeted therapies and therapeutic regimens. There are currently over 30 new agents being tested in the treatment of multiple myeloma (MM). Many of these are novel, targeted agents that have demonstrated significant efficacy and prolonged survival. In this review, we summarize the current understanding of the mechanisms of action of novel therapies being tested in the preclinical and clinical settings in MM. These include agents that act directly on the intracellular signaling pathways, cell maintenance processes, and cell surface receptors. Finally, we present the clinical responses to some of these agents when used alone or in combination in clinical trials of patients with MM. Indeed, MM has become a model disease for the development of novel, therapeutic agents.
登录
查看更多内容
影响因子：
7.2
作者：
Chauhan, D;Anderson, KC
通讯作者：
Anderson, KC
影响因子：
20.3
作者：
Barlogie, B;Desikan, R;Tricot, G
通讯作者：
Tricot, G
影响因子：
11.4
作者：
Brunn, GJ;Williams, J;Abraham, RT
通讯作者：
Abraham, RT
影响因子：
20.3
作者：
Alsina, M;Fonseca, R;Sebti, SM
通讯作者：
Sebti, SM
影响因子：
20.3
作者：
Bergsagel, PL;Kuehl, WM;Shaughnessy, J
通讯作者：
Shaughnessy, J